Zirh in Canada
This article was originally published in The Rose Sheet
Executive Summary
Zirh Holding has tapped Quadrant Cosmetics Corp. to distribute its skin care for men in Canada, effective Jan. 1, according to Nov. 27 announcement. "In selecting Quadrant Cosmetics Corp., we wanted to appoint a distributor who had the most complete territory coverage and excellent in-store execution capabilities," Zirh Holdings President and CEO Brian Robinson says. "Additionally, Quadrant's management team was very enthusiastic about the Zirh brand which was a component we were looking for in a distributor." Zirh previously was distributed in Canada by Japanese cosmetic firm Shiseido, which owned the brand from 2000 to 2007. Robinson, who founded the company in 1995 and sold it in 2000, repurchased Zirh from Shiseido in August 2007 (1"The Rose Sheet" Sept. 3, 2007, In Brief). In addition, Zirh announces the appointment of Alyssa Truppelli as internet marketing director, effective Dec. 3. Truppelli was previously the e-commerce manager at MAC Cosmetics...
You may also be interested in...
Shiseido to sell Zirh
Japanese beauty company has entered into an agreement to sell Zirh men's skin-care and fragrance brand and Corduroy men's fragrance brand to a group of private investors led by former Zirh president Brian Robinson, who resigned in 2005 (1"The Rose Sheet" Jan. 3, 2005, In Brief). Zirh International Corp., which markets the affected brands, will be renamed ZIC Corp. and continue to function as a wholly owned Shiseido subsidiary, allowing the company "to focus [its] strengths and invest business resources in the John Varvatos brand and [its] Shiseido Men skin-care line," according to Shuichi Tanaka, chairman and CEO, Shiseido International Corporation. "Brian Robinson has unique experience in the men's skin-care market as well as an intimate working knowledge of the Zirh brand. This transaction will provide the Zirh and Corduroy brands with a business structure better suited for their growth and expansion"...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.